Physician profile
Suzanne Mp Bennett
NPI 1881659936
$5,633.57
in general payments reported to CMS, 2019-2025
19 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.80 · 2020: $25.49 · 2021: $1,476 · 2022: $389 · 2023: $956 · 2024: $1,182 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,695.75 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $1,323.76 | 2021 | |
| Abbvie INC. | $655.83 | 2021-2025 | Ubrelvy |
| Novo Nordisk INC | $454.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $376.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Amgen INC. | $331.44 | 2019-2025 | Repatha, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $201.64 | 2022-2025 | Ajovy, Austedo Xr |
| Pfizer INC. | $142.97 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $132.25 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Shingrix |
| Boston Scientific Corporation | $68.07 | 2021-2024 | Watchman Flx |
| Lilly USA, LLC | $25.66 | 2019-2021 | |
| Acella Pharmaceuticals, LLC | $17.81 | 2025 | NP Thyroid 60 |
| Esperion Therapeutics, INC. | $15.38 | 2021 | |
| Currax Pharmaceuticals LLC | $14.19 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.91 | 2024 | Cologuard Collection Kit |
| Nevro Corp. | $13.63 | 2022 | |
| Allergan, INC. | $13.01 | 2020 | |
| Phadia US INC. | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.